News

PDS Biotechnology has completed subject recruitment for stage 1 of its Phase II trial, evaluating the systemic administration of PDS01ADC.
Pfizer and Astellas’ Xtandi (enzalutamide) has improved overall survival (OS) in patients with nmHSPC, but only as a combination therapy.
XyloCor has dosed the first subject in the multi-centre, randomised Phase IIb EXACT-2 trial to assess the gene therapy candidate, XC001.
UK & Ireland, experts provided insights on market trends within the clinical trial industry and advice on engagement strategies.